| Name | PureTech Health |
|---|---|
| Epic | PRTC |
| Isin | GB00BY2Z0H74 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 142.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £339.98 | Debt ratio | n/a |
| Shares in issue | 239.42 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -7.7 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -24 | 52-week high / low | 139.40p / 237.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | PureTech Health |
|---|---|
| Address | 6 Tide St Ste 400, Boston, United States, MA, 02210- |
| Telephone | |
| Website | http://www.puretechhealth.com |
| Director | Position |
|---|---|
| Mr Bharatt Chowrira | CEO |
| Dr. Raju Kucherlapati | Chairman |
| Dr. Robert Langer | Non-Executive Director |
| Mr H. Robert Horvitz | Non-Executive Director |
| Mr Michele Holcomb | Independent Non-Executive Director |
| Ms Kiran Mazumdar Shaw | Independent Non-Executive Director |
| Ms Sharon Barber-Lui | Independent Non-Executive Director |
| Dr. John LaMattina | Independent Non-Executive Director |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 0.91 | 0.83 | 0.99 |
| Investments and other non-current assets | 325.63 | 277.54 | 397.18 |
| Total non-current assets | 346.77 | 316.45 | 444.2 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 18.43 | 33.97 | 18.86 |
| Cash and equivalents | 191.08 | 149.87 | 465.71 |
| Other current assets and asset held for resale | 1.63 | 2.12 | 17.24 |
| Total of all assets | 693.97 | 702.65 | 946.01 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 51.37 | 96.88 | 226.13 |
| Long term liabilities | 184.37 | 58.17 | 135.72 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 235.74 | 155.06 | 361.86 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 458.23 | 547.59 | 584.15 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 5.46 | 5.46 | 5.44 |
| Minority interests | -5.83 | 5.37 | -9.37 |
| Retained earnings | 83.82 | 149.52 | 199.87 |
| Share premium account | 290.26 | 289.62 | 289.3 |
| Total equity | 458.23 | 547.59 | 584.15 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -146.2 | -197.81 | -150.28 |
| Pre-tax profit | -36.1 | -92.78 | -58.95 |